Synthesis, Structural Characterization, and In Silico ADMET Testing of Novel 17β-Acetoxy-17α-(Pyridin-2-yl) Estrane Derivatives †
Abstract
:Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Stevanović, M.; Kuzminac, I. Synthesis, Structural Characterization, and In Silico ADMET Testing of Novel 17β-Acetoxy-17α-(Pyridin-2-yl) Estrane Derivatives. Med. Sci. Forum 2022, 14, 113. https://doi.org/10.3390/ECMC2022-13235
Stevanović M, Kuzminac I. Synthesis, Structural Characterization, and In Silico ADMET Testing of Novel 17β-Acetoxy-17α-(Pyridin-2-yl) Estrane Derivatives. Medical Sciences Forum. 2022; 14(1):113. https://doi.org/10.3390/ECMC2022-13235
Chicago/Turabian StyleStevanović, Milica, and Ivana Kuzminac. 2022. "Synthesis, Structural Characterization, and In Silico ADMET Testing of Novel 17β-Acetoxy-17α-(Pyridin-2-yl) Estrane Derivatives" Medical Sciences Forum 14, no. 1: 113. https://doi.org/10.3390/ECMC2022-13235
APA StyleStevanović, M., & Kuzminac, I. (2022). Synthesis, Structural Characterization, and In Silico ADMET Testing of Novel 17β-Acetoxy-17α-(Pyridin-2-yl) Estrane Derivatives. Medical Sciences Forum, 14(1), 113. https://doi.org/10.3390/ECMC2022-13235